MILAN — Antidepressants escitalopram and duloxetine have been shown to improve verbal memory in moderate to severe depression, a clinical effect linked to changes in serotonin 4 (5-HT4) receptor ...
(RTTNews) - First Wave BioPharma, Inc., (FWBI) announced an agreement with Sanofi (SNY) to license Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop ...
NEW YORK (Reuters Health) - Scientists from France have found that anorexia and the highly addicting club-drug ecstasy activate some of the same brain pathways, a finding that may help explain the ...
First Wave BioPharma Inc (NASDAQ:FWBI) announced an agreement with Sanofi SA (NASDAQ:SNY) to license Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop ...
Several 5-HT4 receptor (5-HT4R) agonists are approved for treating chronic idiopathic constipation (CIC) by stimulating gastrointestinal (GI) motility. Traditional 5-HT4R agonists act systemically, ...
Silo Pharma Files Patent Application for Alzheimer's Drug SPC-14 Targeting Novel Mechanism of Action
Silo Pharma, Inc. has announced the filing of a patent application for its neurology drug, SPC-14, which is an intranasal treatment for Alzheimer's disease. This compound, licensed from Columbia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback